Exosomal Lipid Biomarkers for Early HCC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hepatocellular carcinoma (HCC) in patients with liver cirrhosis are inadequate due to low sensitivity and specificity of existing surveillance approaches, necessitating the development of innovative biomarkers and diagnostic methods.
Innovation Solution
The detection of HCC biomarkers in exosomes isolated from blood samples using lipid classes such as sphingosine (SPH), sulfatide (ST), and lysophosphatidylserine (LysoPS) through techniques like gas chromatography and ultra-high resolution mass spectrometry, allowing for early stage HCC detection and treatment monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ultrasound and serum AFP are used for HCC surveillance, then the surveillance can be performed routinely, but the sensitivity and specificity remain low
Solution Approach 1:
The patent segments the diagnostic approach by isolating and analyzing specific exosome subpopulations (tumor-derived exosomes vs. stromal exosomes) and their distinct lipid metabolite profiles. This segmentation enables detection of HCC-specific biomarkers that are not detectable by conventional ultrasound or AFP, thereby improving sensitivity and specificity while maintaining a manageable diagnostic workflow
Solution Approach 2:
The patent introduces exosomal lipid metabolites as intermediary biomarkers that mediate between the tumor and the diagnostic system. These metabolites serve as detectable signals that reflect underlying HCC pathology, providing a bridge between the disease state and the detection method, thus improving diagnostic reliability without requiring direct visualization or complex procedures
2Productivity
If HCC surveillance is promoted in patients with cirrhosis, then early detection rate should increase, but current surveillance remains underused in clinical practice
Solution Approach 1:
The patent employs a blood-based exosome analysis approach that leverages routinely collected clinical samples (blood) and automated analytical techniques. This self-service model reduces the need for additional patient visits, specialized equipment, or complex procedures, thereby improving ease of operation and facilitating broader implementation of surveillance programs
Solution Approach 2:
The patent changes the detection parameters from conventional imaging and protein markers to lipid metabolite profiles in exosomes. This parameter change enables detection of HCC at molecular levels, improving early detection rate by identifying disease-specific metabolic alterations that precede anatomical or functional changes detectable by traditional methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the sensitivity and specificity of HCC detection, enabling earlier diagnosis and more effective treatment strategies for patients with liver cirrhosis, improving survival rates by identifying biomarkers that correlate with HCC presence in blood samples.
Implementation Method 1
detecting comprises detection by gas chromatography, mass spectroscopy, gas chromatography-mass spectrometry or liquid chromatograph-mass spectrometry
Implementation Method 2
detecting comprises detection by gas chromatography, mass spectroscopy, gas chromatography-mass spectrometry or liquid chromatograph-mass spectrometry
Implementation Method 3
the mass spectrometry is ultra-high resolution mass spectrometry
Data Source
AI summary
A method of detecting hepatocellular carcinoma (HCC) biomarkers in exosomes isolated from a blood sample obtained from a human subject is provided, by detecting in the sample two or more exosomal HCC biomarkers. The subject can be a healthy patient, a patient suspected of having a liver disorder, a patient previously diagnosed with liver cirrhosis, or a patient previously diagnosed with liver fibrosis.